EGFR and breast carcinoma: Identification of HER2/neu led to the development of trastuzumab (Herceptin), a humanized monoclonalantibody of the IgG1 type directed against the extracellular portion of human EGFR HER2/neu, and revolutionizedthe management of both early and advanced breast cancer.